Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
Clinical trial NCT05007418 · UNKNOWN
Trial details
- NCT number
- NCT05007418
- Sponsor
- Sorrento Therapeutics, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-01
- Primary completion
- 2025-12-01
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.